We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.
We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.
We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.
We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.
We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.
We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.
We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.
We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.
We are studying whether Hydroxychloroquine can help slow kidney function decline in patients with IgA Nephropathy. This trial focuses on those with high levels of protein in their urine despite current treatments.
We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.
We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.
We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.
We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.
We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.
We are studying a new way to give fosfomycin to see if it improves how the body absorbs the medication. This trial is for individuals needing antibiotic treatment.
We are testing whether bladder instillation of neoadjuvant chemotherapy can help prevent recurrence in patients with non-muscle-invasive bladder cancer. This study compares it to standard treatment to assess effectiveness and side effects.
We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.
We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.
We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.
We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.